TSX slightly higher on employment data
Investing.com - H.C. Wainwright reduced its price target on Processa Pharmaceuticals (NASDAQ:PCSA) to $1.00 from $2.00 on Tuesday, while maintaining a Buy rating on the stock. According to InvestingPro data, the company’s stock has declined over 86% in the past year, with current market capitalization at $9.5 million.
The price target reduction reflects recent and projected equity dilution following Processa’s strategic investment announcement. The company secured approximately $1.1 million in net proceeds from the sale of roughly 5.5 million shares of common stock at $0.23 per share. InvestingPro analysis shows the company is quickly burning through cash, though it maintains a healthy current ratio of 3.45x, indicating strong short-term liquidity.
Processa has received a notice from the NASDAQ exchange indicating non-compliance with the minimum bid price requirement due to its low share price. The company has until early 2026 to regain compliance, with H.C. Wainwright expecting Processa to implement a reverse stock split to adjust the stock price above $1 if necessary.
The biopharmaceutical company is also evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives, according to H.C. Wainwright’s research note.
H.C. Wainwright indicated that potential benefits from any cryptocurrency treasury strategy implementation might take several quarters to materialize.
In other recent news, Processa Pharmaceuticals has made several noteworthy announcements. The company has secured a strategic investment and is exploring cryptocurrency treasury strategies to diversify its capital base and enhance financial flexibility. This initiative aims to support their clinical development programs and potentially reduce shareholder dilution. Additionally, Processa Pharmaceuticals will reconvene its Annual Shareholder Meeting after achieving a quorum, with the meeting now scheduled for July 18 in Hanover, Maryland. Previously, the meeting was adjourned due to insufficient proxy votes. In another development, H.C. Wainwright has maintained a Buy rating on Processa Pharmaceuticals, setting a price target of $2.00. The company is prioritizing the clinical development of its lead oncology asset, NGC-Cap, and is planning a new adaptive pivotal Phase 3 study for PCS499 in rare kidney diseases. Processa Pharmaceuticals has also changed the location of its 2025 Special Meeting of Stockholders to Pasadena, California, as decided by the board of directors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.